Press releases
- BRUKINSA® Data at ASCO Underscore Differentiated Clinical Profile for Treatment of CLL and SLL
- BeiGene Highlights New Hematology Portfolio and Pipeline Data at EHA2024
- BeiGene Reports First Quarter 2024 Financial Results and Business Updates
- BeiGene Demonstrates Global Progress in 2023 Responsible Business & Sustainability Report
- Global Oncology Innovator BeiGene Highlights New Data across Hematology and Solid Tumor Portfolio at 2024 ASCO Annual Meeting
- BeiGene Receives European Commission Approval for Tislelizumab as Treatment for Non-Small Cell Lung Cancer
- BeiGene Receives FDA Approval for TEVIMBRA® for the Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma After Prior Chemotherapy
- Pi Health Raises Over $30M in Series A to Revolutionize Cancer Care and Clinical Trials
- First Doses of BRUKINSA® provided to Patients with Chronic Lymphocytic Leukemia in Low- and Middle-Income Countries Under Collaboration of The Max Foundation, BeiGene, and the BeiGene Foundation
- BeiGene Announces FDA Accelerated Approval of BRUKINSA for the Treatment of Relapsed or Refractory Follicular Lymphoma
More ▼
Key statistics
On Friday, Beigene Ltd (688235:SHH) closed at 121.52, 23.37% above the 52 week low of 98.50 set on Feb 05, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 125.34 |
---|---|
High | 127.48 |
Low | 121.52 |
Bid | 121.52 |
Offer | 121.60 |
Previous close | 122.42 |
Average volume | 1.01m |
---|---|
Shares outstanding | 1.36bn |
Free float | 1.29bn |
P/E (TTM) | -- |
Market cap | 115.88bn CNY |
EPS (TTM) | -4.58 CNY |
Data delayed at least 15 minutes, as of May 31 2024.
More ▼